Erythropoietin-stimulating agents — widely used to treat anemia in end-stage renal disease (ESRD) — increase the risk of hip fracture in patients on dialysis, and the higher the dose, the greater the ...

Anemia is a common and sometimes debilitating problem among patients with chronic kidney disease (CKD). Anemia can occur when the kidneys become damaged, limiting the production of erythropoietin (EPO ...

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), in end-stage ...

SEOUL, South Korea--(BUSINESS WIRE)--Genexine (KQ 095700, CEO Sungjune Hong), a publicly-listed clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel ...

Anemia in chronic kidney disease (CKD) causes the body to produce too few red blood cells. People with advanced kidney disease tend to develop this condition, and it can increase the risk of negative ...

EPO, an important drug for treating anemia, can now be produced in higher quantities and with better quality in mammalian cells designed using CRISPR. To many people, EPO rhymes with doping and ...

Please provide your email address to receive an email when new articles are posted on . Jay B. Wish, MD: The quality of life was terrible. Patients felt tired all the time; they had no energy, no ...

In the article that accompanies this editorial, the authors' trial results indicate that roxadustat, a proline hydroxylase inhibitor, was noninferior to erythropoiesis-stimulating agent therapy in ...

Source: Getty Images Addressing anemia in CKD requires a proactive, multifaceted approach, incorporating both conventional and nutritional strategies. Early recognition and intervention are essential ...

A 45-year-old woman with stage 5 chronic kidney disease (CKD) due to lupus nephritis visits the nephrology clinic for routine follow-up. She has no overt uremic symptoms. There is no shortness of ...